TEVA Q1 2020 Earnings — Teva Pharmaceutical Industries Limited Revenue & Financial Results | Market Cap Arena

TEVATeva Pharmaceutical Industries Limited

$36B

Q1 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$4.4B+1.4% YoY

Gross Profit

$2.1B47.3% margin

Operating Income

$191M4.4% margin

Net Income

$69M1.6% margin

EPS (Diluted)

$0.06

QoQ Revenue Growth

-2.5%

Cash Flow

Operating Cash Flow

$305M

Free Cash Flow

$177M

Stock-Based Comp.

$30M

Balance Sheet

Total Assets

$55.3B

Total Liabilities

$40.7B

Stockholders' Equity

$13.5B

Cash & Equivalents

$1.8B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4.4B	$4.3B	+1.4%
Gross Profit	$2.1B	$1.9B	+11.2%
Operating Income	$191M	$134M	+42.5%
Net Income	$69M	-$105M	+165.7%

Revenue Segments

Product

$3.7B84%

Distribution Service

$434M10%

Product and Service, Other

$227M5%

License

$41M1%

Geographic Segments

North America Segment

$2.1B51%

Europe Segment

$1.4B35%

International Markets

$565M14%